DR1

Summary

DR1 (down-regulator of transcription 1, HGNC:3017) is a protein-coding gene on chromosome 1p22.1, encoding Protein Dr1 (Q01658). The association of the DR1/DRAP1 heterodimer with TBP results in a functional repression of both activated and basal transcription of class II genes. It is a selective cancer dependency (DepMap: 87.5% of cell lines).

This gene encodes a TBP- (TATA box-binding protein) associated phosphoprotein that represses both basal and activated levels of transcription. The encoded protein is phosphorylated in vivo and this phosphorylation affects its interaction with TBP. This protein contains a histone fold motif at the amino terminus, a TBP-binding domain, and a glutamine- and alanine-rich region. The binding of DR1 repressor complexes to TBP-promoter complexes may establish a mechanism in which an altered DNA conformation, together with the formation of higher order complexes, inhibits the assembly of the preinitiation complex and controls the rate of RNA polymerase II transcription.

Source: NCBI Gene 1810 — RefSeq curated summary.

At a glance

• GWAS associations: 30
• Clinical variants (ClinVar): 11 total
• Cancer dependency (DepMap): dependent in 87.5% of screened cell lines
• MANE Select transcript: NM_001938

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3017
Approved symbol	DR1
Name	down-regulator of transcription 1
Location	1p22.1
Locus type	gene with protein product
Status	Approved
Aliases	NC2-BETA, NC2B, NCB2
Ensembl gene	ENSG00000117505
Ensembl biotype	protein_coding
OMIM	601482
Entrez	1810

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 3 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000370267, ENST00000370272, ENST00000481583, ENST00000937480

RefSeq mRNA: 1 — MANE Select: NM_001938 NM_001938

CCDS: CCDS744

Canonical transcript exons

ENST00000370272 — 3 exons

Exon	Start	End
ENSE00000777038	93353908	93354071
ENSE00001452227	93360493	93369493
ENSE00001452230	93345907	93346865

Expression profiles

Bgee: expression breadth ubiquitous, 294 present calls, max score 98.09.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 50.7236 / max 257.0457, expressed in 1820 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
4059	49.8547	1819
4061	0.5216	202
4060	0.3473	110

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
choroid plexus epithelium	UBERON:0003911	98.09	gold quality
penis	UBERON:0000989	96.89	gold quality
adult organism	UBERON:0007023	96.60	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	96.09	gold quality
amniotic fluid	UBERON:0000173	96.04	gold quality
buccal mucosa cell	CL:0002336	95.94	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	95.90	gold quality
biceps brachii	UBERON:0001507	95.63	gold quality
upper leg skin	UBERON:0004262	95.27	gold quality
tibia	UBERON:0000979	95.16	gold quality
body of tongue	UBERON:0011876	95.05	gold quality
oral cavity	UBERON:0000167	94.96	gold quality
superficial temporal artery	UBERON:0001614	94.62	gold quality
skin of hip	UBERON:0001554	94.53	gold quality
heart right ventricle	UBERON:0002080	94.53	gold quality
urethra	UBERON:0000057	94.18	gold quality
synovial joint	UBERON:0002217	94.12	gold quality
superior surface of tongue	UBERON:0007371	94.11	gold quality
seminal vesicle	UBERON:0000998	93.99	gold quality
bone marrow	UBERON:0002371	93.99	gold quality
trabecular bone tissue	UBERON:0002483	93.99	gold quality
tongue	UBERON:0001723	93.96	gold quality
monocyte	CL:0000576	93.79	gold quality
mononuclear cell	CL:0000842	93.71	gold quality
leukocyte	CL:0000738	93.68	gold quality
jejunum	UBERON:0002115	93.51	gold quality
pigmented layer of retina	UBERON:0001782	93.45	gold quality
cartilage tissue	UBERON:0002418	93.42	gold quality
lateral nuclear group of thalamus	UBERON:0002736	93.35	gold quality
germinal epithelium of ovary	UBERON:0001304	93.08	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	10.74
E-MTAB-7303	no	36.28

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

4 targets.

Target	Regulation
NR1I2	Activation
NR2C2	Unknown
PTGS2	Activation
TBP	Repression

Upstream regulators (CollecTRI, top): BTAF1, HNF4A, NCOA2, NR0B1, NR1H4, NR1I3, NR2F1, NR2F2, TBP, ZIC1

miRNA regulators (miRDB)

177 targeting DR1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-340-5P	100.00	72.50	4437
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-1250-3P	99.96	70.04	4038

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 87.5% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 11)

• NC2 controls TBP binding and maintenance on DNA that is largely independent of a canonical TATA sequence (PMID:15574413)
• the initiator core promoter element antagonizes repression of TATA-directed transcription by negative cofactor NC2 (PMID:17584739)
• Data show that NC2beta is specifically involved in neuroblastoma pathogenesis and may be considered a new neuroblastoma biomarker. (PMID:18538002)
• ATAC Is a GCN5/PCAF-containing acetylase complex with a novel NC2-like histone fold module that interacts with the TATA-binding protein (PMID:18838386)
• heterodimerization with NC2alpha masks the nuclear localization signal in NC2beta, which prevents nuclear export of the NC2 complex (PMID:19204005)
• The physiological functions of human Dr1 include regulation of polymerase III transcription. (PMID:19965767)
• Basal core promoters control the equilibrium between negative cofactor 2 and preinitiation complexes in human cells. (PMID:20230619)
• Knockdown of DR1 resulted in reductions of viral RNA and protein production, demonstrating that DR1 acts as a positive host factor in influenza A virus replication. (PMID:25589657)
• results suggest that DR1 are expressed in the osteosarcoma cells and inhibit the proliferation of osteosarcoma cells by the down-regulation of the ERK1/2 and PI3K-Akt pathways. (PMID:28181134)
• Up-regulation of microRNA-203 in influenza A virus infection inhibits viral replication by targeting DR1. (PMID:29717211)
• Downregulation of transcription 1 hinders the replication of Dabie bandavirus by promoting the expression of TLR7, TLR8, and TLR9 signaling pathway. (PMID:38194758)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	dr1	ENSDARG00000105098
mus_musculus	Dr1	ENSMUSG00000029265
rattus_norvegicus	Dr1	ENSRNOG00000000070
drosophila_melanogaster	NC2beta	FBGN0028926
caenorhabditis_elegans		WBGENE00001092

Paralogs (2): NFYB (ENSG00000120837), FAM47E (ENSG00000189157)

Protein

Protein identifiers

Protein Dr1 — Q01658 (reviewed: Q01658)

Alternative names: Down-regulator of transcription 1, Negative cofactor 2-beta, TATA-binding protein-associated phosphoprotein

All UniProt accessions (2): Q01658, Q658N3

UniProt curated annotations — full annotation on UniProt →

Function. The association of the DR1/DRAP1 heterodimer with TBP results in a functional repression of both activated and basal transcription of class II genes. This interaction precludes the formation of a transcription-competent complex by inhibiting the association of TFIIA and/or TFIIB with TBP. Can bind to DNA on its own. Component of the ATAC complex, a complex with histone acetyltransferase activity on histones H3 and H4.

Subunit / interactions. Heterodimer with DRAP1. DR1 exists in solution as a homotetramer that dissociates during interaction with TBP and then, after complexing with TBP, reassociates at a slow rate, to reconstitute the tetramer. Interacts with NFIL3. Component of the ADA2A-containing complex (ATAC), composed of KAT14, KAT2A, TADA2L, TADA3L, ZZ3, MBIP, WDR5, YEATS2, CCDC101 and DR1.

Subcellular location. Nucleus.

Post-translational modifications. Phosphorylation regulates its interaction with TBP. Not phosphorylated when bound to DRAP1.

Similarity. Belongs to the NC2 beta/DR1 family.

RefSeq proteins (1): NP_001929* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003958	CBFA_NFYB_domain	Domain
IPR009072	Histone-fold	Homologous_superfamily
IPR042225	Ncb2	Family

Pfam: PF00808

UniProt features (20 total): helix 6, modified residue 5, strand 2, initiator methionine 1, chain 1, sequence variant 1, domain 1, region of interest 1, short sequence motif 1, compositionally biased region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
1JFI	X-RAY DIFFRACTION	2.62

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q01658-F1	87.84	0.73

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 167, 2, 105, 106, 166

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-3214847	HATs acetylate histones
R-HSA-9772755	Formation of WDR5-containing histone-modifying complexes
R-HSA-212165	Epigenetic regulation of gene expression
R-HSA-3247509	Chromatin modifying enzymes
R-HSA-4839726	Chromatin organization
R-HSA-74160	Gene expression (Transcription)
R-HSA-9917777	Epigenetic regulation by WDR5-containing histone modifying complexes

MSigDB gene sets: 270 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_UP, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_CONTAINING_COMPLEX_ASSEMBLY, AAGCAAT_MIR137, WANG_CLIM2_TARGETS_UP, GOBP_REGULATION_OF_PROTEIN_DEACETYLATION, GOZGIT_ESR1_TARGETS_DN, GOBP_MACROMOLECULE_DEACYLATION, MORF_HDAC1, MORF_UBE2N, TATTATA_MIR374, GENTILE_RESPONSE_CLUSTER_D3, BROWNE_HCMV_INFECTION_16HR_UP, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION, WEI_MYCN_TARGETS_WITH_E_BOX

GO Biological Process (8): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of DNA-templated transcription (GO:0006355), regulation of transcription by RNA polymerase II (GO:0006357), regulation of embryonic development (GO:0045995), RNA polymerase II preinitiation complex assembly (GO:0051123), regulation of cell division (GO:0051302), regulation of cell cycle (GO:0051726), DNA-templated transcription (GO:0006351)

GO Molecular Function (6): DNA binding (GO:0003677), RNA polymerase II general transcription initiation factor activity (GO:0016251), TBP-class protein binding (GO:0017025), protein heterodimerization activity (GO:0046982), protein binding (GO:0005515), general transcription initiation factor activity (GO:0140223)

GO Cellular Component (6): nucleoplasm (GO:0005654), negative cofactor 2 complex (GO:0017054), mitotic spindle (GO:0072686), RNA polymerase II transcription regulator complex (GO:0090575), ATAC complex (GO:0140672), nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Chromatin modifying enzymes	1
Epigenetic regulation by WDR5-containing histone modifying complexes	1
Gene expression (Transcription)	1
Chromatin organization	1
Epigenetic regulation of gene expression	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transcription by RNA polymerase II	3
DNA-templated transcription	2
regulation of cellular process	2
regulation of transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
regulation of DNA-templated transcription	1
embryo development	1
regulation of multicellular organismal development	1
transcription initiation at RNA polymerase II promoter	1
transcription preinitiation complex assembly	1
cell division	1
cell cycle	1
gene expression	1
RNA biosynthetic process	1
nucleic acid binding	1
general transcription initiation factor activity	1
general transcription initiation factor binding	1
protein dimerization activity	1
binding	1
molecular_function	1
nuclear lumen	1
cellular anatomical structure	1
RNA polymerase II transcription repressor complex	1
spindle	1
transcription regulator complex	1
nuclear protein-containing complex	1
SAGA-type complex	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1274 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DR1	DRAP1	Q14919	990
DR1	COL18A1	P39060	959
DR1	TBP	P20226	953
DR1	YEATS2	Q9ULM3	858
DR1	MBIP	Q9NS73	842
DR1	CENPW	Q5EE01	792
DR1	GTF2B	Q00403	777
DR1	COL8A1	P27658	762
DR1	BTAF1	O14981	712
DR1	CFAP20	Q9Y6A4	702
DR1	COL7A1	Q02388	689
DR1	ZZZ3	Q8IYH5	686
DR1	WDR5	P61964	684
DR1	COL8A2	P25067	669
DR1	PPARG	P37231	641

IntAct

303 interactions, top by confidence:

A	B	Type	Score
DR1	DRAP1	psi-mi:“MI:0915”(physical association)	0.950
DR1	DRAP1	psi-mi:“MI:2364”(proximity)	0.950

BioGRID (151): TBP (Two-hybrid), POLE3 (Two-hybrid), DR1 (Two-hybrid), DR1 (Affinity Capture-MS), DR1 (Affinity Capture-MS), DR1 (Affinity Capture-MS), DR1 (Affinity Capture-MS), DR1 (Affinity Capture-MS), POLE3 (Two-hybrid), CCDC101 (Co-fractionation), COPS3 (Co-fractionation), DR1 (Co-fractionation), DRAP1 (Co-fractionation), DR1 (Affinity Capture-MS), DRAP1 (Co-fractionation)

ESM2 similar proteins: A0MQH0, A2AWA9, A4FUD6, A6QL63, A6QR06, A7MAZ4, B5KFI0, O75486, P54198, P70398, P79987, Q01658, Q148V7, Q1LVW0, Q3ZBE1, Q503N9, Q5BJQ7, Q5R8N4, Q5RAN1, Q5RCC1, Q5RCR8, Q5RCW6, Q5RDB9, Q5XI68, Q5ZMQ0, Q5ZMS1, Q5ZMV3, Q61666, Q62784, Q6GMF2, Q6GQW0, Q7Z7C8, Q7ZYA2, Q8BHL5, Q8BPU7, Q8R418, Q8VHE0, Q91WV0, Q92556, Q93008

Diamond homologs: B0Y0F3, O04027, O14348, O17286, O23310, O82248, P13434, P25207, P25208, P25209, P25210, P36611, P40914, P49592, P63139, P63140, Q01658, Q0J7P4, Q32KW0, Q4WFF8, Q54WV0, Q55DJ5, Q5QMG3, Q5XI68, Q5ZMV3, Q60EQ4, Q65XK1, Q67XJ2, Q69J40, Q6BIP4, Q6RG77, Q75IZ7, Q84W66, Q8VYK4, Q91WV0, Q92317, Q9FGJ3, Q9SFD8, Q9SIT9, Q9SLG0

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
DR1	“form complex”	“NC2 complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 86 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Formation of WDR5-containing histone-modifying complexes	5	30.2×	1e-04
Epigenetic regulation by WDR5-containing histone modifying complexes	5	17.5×	7e-04
Epigenetic regulation of gene expression	8	13.0×	7e-05
Chromatin organization	7	13.0×	1e-04
Chromatin modifying enzymes	7	11.5×	2e-04

GO biological processes:

GO term	Partners	Fold	FDR
regulation of cell division	5	50.4×	2e-05
regulation of embryonic development	6	26.1×	3e-05
chromatin remodeling	7	6.7×	8e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

11 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	6
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

461 predictions. Top by Δscore:

Variant	Effect	Δscore
1:93346862:CAAGG:C	donor_loss	1.0000
1:93346864:AGGT:A	donor_loss	1.0000
1:93346866:GT:G	donor_loss	1.0000
1:93353906:A:AG	acceptor_gain	1.0000
1:93353907:G:GG	acceptor_gain	1.0000
1:93354067:CAAAA:C	donor_gain	1.0000
1:93354068:AAAA:A	donor_gain	1.0000
1:93354069:AAA:A	donor_gain	1.0000
1:93354070:AA:A	donor_gain	1.0000
1:93354070:AAGT:A	donor_loss	1.0000
1:93354071:AGT:A	donor_loss	1.0000
1:93354072:G:GG	donor_gain	1.0000
1:93360483:G:A	acceptor_gain	1.0000
1:93360650:C:G	donor_gain	1.0000
1:93346867:T:G	donor_loss	0.9900
1:93353907:GC:G	acceptor_gain	0.9900
1:93353907:GCA:G	acceptor_gain	0.9900
1:93353907:GCACT:G	acceptor_gain	0.9900
1:93354073:TAA:T	donor_loss	0.9900
1:93355980:T:G	donor_gain	0.9900
1:93360482:T:TA	acceptor_gain	0.9900
1:93360492:GGCTA:G	acceptor_gain	0.9900
1:93360650:C:CG	donor_gain	0.9900
1:93353903:TCTA:T	acceptor_loss	0.9800
1:93353906:A:AC	acceptor_loss	0.9800
1:93354075:A:AG	donor_gain	0.9800
1:93354076:G:GG	donor_gain	0.9800
1:93360477:T:G	acceptor_gain	0.9800
1:93360492:GGCT:G	acceptor_gain	0.9800
1:93346866:G:GG	donor_gain	0.9700

AlphaMissense

1158 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:93346685:C:T	P14S	1.000
1:93346686:C:A	P14H	1.000
1:93346686:C:T	P14L	1.000
1:93346690:A:C	R15S	1.000
1:93346690:A:T	R15S	1.000
1:93346692:C:A	A16D	1.000
1:93346695:C:A	A17D	1.000
1:93346703:A:G	K20E	1.000
1:93346705:A:C	K20N	1.000
1:93346705:A:T	K20N	1.000
1:93346712:A:G	K23E	1.000
1:93346713:A:T	K23I	1.000
1:93346714:A:C	K23N	1.000
1:93346714:A:T	K23N	1.000
1:93346737:T:A	V31E	1.000
1:93346748:G:C	A35P	1.000
1:93346749:C:A	A35D	1.000
1:93346752:G:C	R36P	1.000
1:93346758:T:C	L38P	1.000
1:93346769:T:C	C42R	1.000
1:93346772:T:C	C43R	1.000
1:93346773:G:A	C43Y	1.000
1:93346774:C:G	C43W	1.000
1:93346781:T:C	F46L	1.000
1:93346782:T:C	F46S	1.000
1:93346783:C:A	F46L	1.000
1:93346783:C:G	F46L	1.000
1:93346785:T:A	I47N	1.000
1:93346791:T:C	L49P	1.000
1:93346796:T:C	S51P	1.000

dbSNP variants (sampled 300 via entrez): RS1000141571 (1:93360334 G>A), RS1000209246 (1:93358820 C>T), RS1000310400 (1:93356965 G>A), RS1000494221 (1:93360743 C>T), RS1001291617 (1:93347757 C>G), RS1001743054 (1:93347458 G>A), RS1002311781 (1:93368030 A>T), RS1002321041 (1:93360855 A>G), RS1002375660 (1:93350129 A>C), RS1002383699 (1:93367838 C>G,T), RS1002428132 (1:93349726 A>T), RS1002652805 (1:93362517 G>A), RS1002673818 (1:93361050 G>GGGA,GGGC,GGGGGT), RS1002814172 (1:93348173 G>A), RS1002822939 (1:93356711 T>A,C,G)

Disease associations

OMIM: gene MIM:601482 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

30 associations (top):

Study	Trait	p-value
GCST006003_1	Triglyceride levels	6.000000e-10
GCST008070_127	HDL cholesterol levels	6.000000e-09
GCST008070_62	HDL cholesterol levels	3.000000e-15
GCST008074_12	Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	1.000000e-06
GCST008074_83	Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	1.000000e-06
GCST008075_164	HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	4.000000e-28
GCST008075_216	HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	5.000000e-10
GCST008075_35	HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	1.000000e-17
GCST008083_31	Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	9.000000e-07
GCST008083_96	Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	6.000000e-07
GCST008084_1	HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	3.000000e-17
GCST008084_115	HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	4.000000e-12
GCST008084_213	HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	4.000000e-31
GCST008085_144	HDL cholesterol levels in current drinkers	8.000000e-12
GCST008085_61	HDL cholesterol levels in current drinkers	3.000000e-19
GCST008085_89	HDL cholesterol levels in current drinkers	3.000000e-07
GCST008087_2	Triglyceride levels in current drinkers	3.000000e-06
GCST008477_27	Emphysema annual change measurement in smokers (adjusted lung density)	1.000000e-06
GCST008972_70	Urate levels	3.000000e-10
GCST009602_78	Metabolic syndrome	2.000000e-08
GCST010241_137	Apolipoprotein A1 levels	3.000000e-22
GCST010242_483	HDL cholesterol levels	9.000000e-32
GCST010244_140	Triglyceride levels	9.000000e-13
GCST011345_27	Triglyceride levels	1.000000e-10
GCST011348_65	High density lipoprotein cholesterol levels	2.000000e-14
GCST90002397_638	Mean spheric corpuscular volume	6.000000e-11
GCST90002403_12	Red blood cell count	4.000000e-10
GCST90011898_70	Alanine aminotransferase levels	2.000000e-10
GCST90011900_41	Serum alkaline phosphatase levels	2.000000e-12
GCST90013406_189	Liver enzyme levels (alkaline phosphatase)	2.000000e-15

EFO canonical traits (9, from GWAS)

EFO ID	Trait name
EFO:0004530	triglyceride measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0004329	alcohol drinking
EFO:0007626	emphysema imaging measurement
EFO:0004531	urate measurement
EFO:0000195	metabolic syndrome
EFO:0004614	apolipoprotein A 1 measurement
EFO:0004305	erythrocyte count
EFO:0004533	alkaline phosphatase measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tetrachlorodibenzodioxin	decreases expression, affects expression	2
Valproic Acid	decreases methylation, increases expression	2
Cyclosporine	increases expression	2
aristolochic acid I	increases expression	1
bisphenol A	decreases expression	1
geraniol	decreases expression	1
sodium arsenite	increases expression	1
cobaltous chloride	decreases expression	1
manganese chloride	decreases expression	1
beta-methylcholine	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
ICG 001	decreases expression	1
abrine	increases expression	1
Grape Seed Proanthocyanidins	affects cotreatment, increases expression	1
eprenetapopt	affects reaction, affects expression	1
LDN 193189	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Leflunomide	increases expression	1
Air Pollutants	affects expression, increases abundance	1
Caffeine	affects phosphorylation	1
Catechin	affects cotreatment, increases expression	1
Clozapine	decreases expression	1
Diethylstilbestrol	decreases expression	1
Enzyme Inhibitors	increases O-linked glycosylation, decreases activity	1
Haloperidol	decreases expression	1
Hydrogen Peroxide	affects expression	1
Manganese	decreases expression	1
Methyl Methanesulfonate	increases expression	1
Ozone	affects expression, increases abundance	1
Selenium	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2W1	Abcam HEK293T DR1 KO	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.